Orr B, Mahdi H, Fang Y, Strange M, et al. Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity. Clin Cancer Res 2022 Jan 19. pii: 1078-0432.CCR-21-3659.
PMID: 35046055